Company: TBPH
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0001558370-25-002447
Chunk: 10

Company: Theravance Biopharma, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 15
Chunk 10
---
ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)The following documents are filed as part of this Annual Report on Form 10-K:

1.Financial Statements:

The following financial statements and schedules of the Registrant have been appended to this Annual Report on Form 10-K:

Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)​F-2Consolidated Balance Sheets as of December 31, 2024 and 2023​F-5Consolidated Statements of Operations for each of the two years in the period ended December 31, 2024​F-6Consolidated Statements of Comprehensive Loss for each of the two years in the period ended December 31, 2024​F-7Consolidated Statements of Shareholders’ Equity for each of the two years in the period ended December 31, 2024​F-8Consolidated Statements of Cash Flows for each of the two years in the period ended December 31, 2024​F-9Notes to Consolidated Financial Statements​F-10Supplementary Financial Data (unaudited)​F-39

​

2.Financial Statement Schedules:

All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.

(b)Exhibits required by Item 601 of Regulation S-K

The information required by this Item is set forth on the exhibit index that precedes the signature page of this report.

​